4 High-Growth GARP Stocks With Attractive PEG Ratios for 2026
These four GARP stocks combine discounted PEG ratios with strong growth potential, offering investors a balanced strategy for 2026.
DVA - DaVita Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$202.25
DETAILS
HIGH:
$220.00
LOW:
$190.00
MEDIAN:
$199.50
CONSENSUS:
$202.25
UPSIDE:
1.88%
Stock News
4 Stocks Trading Near 52-Week High With Room to Rise Further
Investors target stocks that have been on a bullish run. Stocks like MUSA, DVA, MCHP and CVE are seeing price strength, and the momentum is likely to continue.
Best Value Stocks to Buy for May 21st
GPRE, DVA and SNX made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 21, 2026.
Best Growth Stocks to Buy for May 21st
DVA, TAL, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 21, 2026.
Best Value Stocks to Buy for May 19th
UVE, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 19, 2026.
Best Growth Stocks to Buy for May 19th
DVA, PBI, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 19, 2026.
DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals
DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals PR Newswire DENVER, M
DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals
Kidney care leader launches its next chapter of measurable impact for patients, teammates, and communities. DENVER, May 18, 2026 /PRNewswire/ -- DaVita today announced its 2030 Community Care commitments, a new set of long-term goals, focused on improving patient outcomes, supporting the expansion of economic opportunity for teammates, and strengthening community and environmental resilience.
4 Best Low-PEG Value Stocks to Bet On for Higher Returns
Low-PEG stocks like DaVita, AR, PBF and Popular stand out as value plays with strong growth potential and discounted valuations.
Best Growth Stocks to Buy for May 14th
NXST, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 14th, 2026.
DaVita Inc. (DVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DaVita Inc. (DVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Best Growth Stocks to Buy for May 12th
AR, DVA and WOOF made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 12th, 2026.
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
DaVita HealthCare (DVA) Is Up 30.99% in One Week: What You Should Know
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Surging Earnings Estimates Signal Upside for DaVita HealthCare (DVA) Stock
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Best Growth Stocks to Buy for May 8th
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today May 8th:
Best Value Stocks to Buy for May 8th
ATLC, DVA and AMN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 8, 2026.
Should Value Investors Buy DaVita (DVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Price Targets
DaVita price target raised to $205 from $158 at Truist
$205.00
(was $194.38)
Truist Financial
DaVita price target raised to $194 from $158 at Barclays
$194.00
(was $193.88)
Andrew Mok
·
Barclays
DaVita upgraded to Buy from Hold at Deutsche Bank
$220.00
(was $157.04)
Pito Chickering
·
Deutsche Bank
DaVita price target raised to $158 from $128 at Truist
$158.00
(was $144.41)
Truist Financial
DaVita price target raised to $190 from $186 at UBS
$190.00
(was $134.73)
UBS
DaVita price target raised to $158 from $143 at Barclays
$158.00
(was $111.19)
Barclays
DaVita price target lowered to $143 from $149 at Barclays
$143.00
(was $126.56)
Barclays
DaVita price target lowered to $140 from $148 at Truist
$140.00
(was $123.36)
David MacDonald
·
Truist Financial
DaVita price target lowered to $149 from $160 at Barclays
$149.00
(was $127.89)
Andrew Mok
·
Barclays
DaVita price target lowered to $148 from $164 at Truist
$148.00
(was $129.54)
David MacDonald
·
Truist Financial
Warren Buffett's Berkshire Hathaway Sells $116M Shares Of Dialysis Giant DaVita, Cuts Stake By 2%
$184.00
(was $142.40)
Lisa Bedell Clive
·
Bernstein
DaVita price target raised to $145 from $139 at BofA
$145.00
(was $133.53)
Kevin Fischbeck
·
Bank of America Securities
DaVita price target raised to $150 from $133 at Barclays
$150.00
(was $134.45)
Andrew Mok
·
Barclays
DaVita price target lowered to $81 from $103 at Barclays
$81.00
(was $70.54)
Sarah James
·
Barclays
UBS Assumes DaVita (DVA) with a Buy
$117.00
(was $93.10)
Andrew Mok
·
UBS
DaVita (DVA) Stock: $90 Target And Hold Rating
$90.00
(was $79.44)
David MacDonald
·
Truist Financial